IRWDIRONWOOD PHARMACEUTICALS INC

Nasdaq ironwoodpharma.com


$ 4.77 $ 0.00 (0 %)    

Tuesday, 20-Aug-2024 15:59:55 EDT
QQQ $ 480.15 $ -1.15 (-0.24 %)
DIA $ 408.54 $ -0.35 (-0.09 %)
SPY $ 558.65 $ -0.51 (-0.09 %)
TLT $ 98.68 $ 0.38 (0.39 %)
GLD $ 232.46 $ -1.26 (-0.54 %)
$ 4.77
$ 4.77
$ 4.77 x 300
$ 4.78 x 1,500
$ 4.51 - $ 4.80
$ 3.79 - $ 15.70
2,187,558
na
756.91M
$ 0.43
$ 82.17
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2024 06-30-2024 10-Q
2 05-09-2024 03-31-2024 10-Q
3 02-16-2024 12-31-2023 10-K
4 11-09-2023 09-30-2023 10-Q
5 08-09-2023 06-30-2023 10-Q
6 05-04-2023 03-31-2023 10-Q
7 02-16-2023 12-31-2022 10-K
8 11-03-2022 09-30-2022 10-Q
9 08-04-2022 06-30-2022 10-Q
10 05-05-2022 03-31-2022 10-Q
11 02-17-2022 12-31-2021 10-K
12 11-04-2021 09-30-2021 10-Q
13 08-05-2021 06-30-2021 10-Q
14 05-06-2021 03-31-2021 10-Q
15 02-17-2021 12-31-2020 10-K
16 11-05-2020 09-30-2020 10-Q
17 08-06-2020 06-30-2020 10-Q
18 05-06-2020 03-31-2020 10-Q
19 02-13-2020 12-31-2019 10-K
20 10-31-2019 09-30-2019 10-Q
21 07-30-2019 06-30-2019 10-Q
22 05-02-2019 03-31-2019 10-Q
23 02-25-2019 12-31-2018 10-K
24 11-06-2018 09-30-2018 10-Q
25 08-06-2018 06-30-2018 10-Q
26 05-04-2018 03-31-2018 10-Q
27 02-22-2018 12-31-2017 10-K
28 11-02-2017 09-30-2017 10-Q
29 08-03-2017 06-30-2017 10-Q
30 05-08-2017 03-31-2017 10-Q
31 02-22-2017 12-31-2016 10-K
32 11-07-2016 09-30-2016 10-Q
33 08-08-2016 06-30-2016 10-Q
34 05-10-2016 03-31-2016 10-Q
35 02-19-2016 12-31-2015 10-K
36 11-05-2015 09-30-2015 10-Q
37 08-07-2015 06-30-2015 10-Q
38 05-06-2015 03-31-2015 10-Q
39 02-18-2015 12-31-2014 10-K
40 11-05-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 wells-fargo-maintains-overweight-on-ironwood-pharmaceuticals-lowers-price-target-to-12

Wells Fargo analyst Mohit Bansal maintains Ironwood Pharmaceuticals (NASDAQ:IRWD) with a Overweight and lowers the price tar...

 craig-hallum-maintains-buy-on-ironwood-pharmaceuticals-lowers-price-target-to-10

Craig-Hallum analyst Chase Knickerbocker maintains Ironwood Pharmaceuticals (NASDAQ:IRWD) with a Buy and lowers the price ta...

 ironwood-has-revised-its-fy-2024-financial-guidance-due-to-continued-linzess-pricing-pressure-due-to-higher-than-expected-medicaid-utilization-trends-for-fy-2024-it-expects-sales-of-350m-375m-compared-to-prior-range-of-405m-425m-and-consensus-of-41005m

Prior 2024 Guidance (May 9, 2024)Revised 2024 Guidance (August 8, 2024)U.S. LINZESS Net SalesMid-single digits % decline2Total ...

 ironwood-pharmaceuticals-appoints-sravan-k-emany-as-senior-vice-president-chief-operating-officer-and-chief-financial-officer-emany-previously-served-as-senior-vice-president-cfo-since-december-2021

- Form8

 ironwood-pharmaceuticals-will-present-late-breaking-data-during-the-2024-digestive-disease-week-meeting-from-its-phase-3-stars-trial-of-apraglutide-for-short-bowel-syndrome-with-intestinal-failure

New data highlight both stoma and colon-in-continuity (CIC) patients drove the positive primary endpoint with significant rel...

 craig-hallum-maintains-buy-on-ironwood-pharmaceuticals-lowers-price-target-to-14

Craig-Hallum analyst Chase Knickerbocker maintains Ironwood Pharmaceuticals (NASDAQ:IRWD) with a Buy and lowers the price ta...

 ironwood-pharmaceuticals-lowers-2024-guidance-now-expects-sales-between-405m-425m-prior-435m-455m-vs-4479m-consensus-sees-adjusted-ebitda-above-120m

Ironwood 2024 Financial Guidance. Ironwood has revised its FY 2024 financial guidance due to a LINZESS gross-to-net change in...

 ironwood-pharmaceuticals-q1-2024-adj-eps-002-misses-019-estimate-sales-74877m-miss-105804m-estimate

Ironwood Pharmaceuticals (NASDAQ:IRWD) reported quarterly losses of $(0.02) per share which missed the analyst consensus estima...

 ironwood-pharmaceuticals-announces-results-from-phase-2-exploratory-stargaze-trial-of-apraglutide-for-steroid-refractory-gastrointestinal-acute-graft-versus-host-disease

First prospective trial of a glucagon-like peptide (GLP-2) analog in SR GI aGVHD. Results up to Day 91 show that apraglutide...

 top-3-health-care-stocks-that-could-lead-to-your-biggest-gains-in-march

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

 wells-fargo-maintains-overweight-on-ironwood-pharmaceuticals-lowers-price-target-to-14

Wells Fargo analyst Mohit Bansal maintains Ironwood Pharmaceuticals (NASDAQ:IRWD) with a Overweight and lowers the price tar...

 why-butterfly-network-shares-are-trading-lower-by-22-here-are-other-stocks-moving-in-thursdays-mid-day-session

Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed four...

 why-is-gastrointestinal-healthcare-focused-ironwood-pharmaceuticals-stock-sinking-on-thursday

Ironwood Pharmaceuticals' SBS-IF treatment Apraglutide's Phase 3 trial met primary endpoints, reducing PS dependency by...

 nasdaq-gains-100-points-following-pce-data

U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining around 100 points on Thursday. Following the ...

 tech-stocks-set-to-rise-thursday-as-january-inflation-data-fails-to-scare-markets-small-caps-surge

Tech stocks drive pre-market surge, Fed inflation data fails to disrupt rate cut expectations. Futures up for Nasdaq, S&P 5...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION